Skip to Content
The sprawling 134-year-old health conglomerate eked out 0.6% sales growth in 2019 thanks to the strong performance of its pharmaceutical business, and particularly its immunology and oncology drugs. J&J’s consumer business—with a portfolio that includes Neutrogena, Tylenol, and Listerine—was boosted by the acquisition of Zarbee’s, a purveyor of naturally based over-the-counter remedies. The company continued its push into the robotic surgery market in an effort to revive its struggling medical device business. J&J is also mired in litigation surrounding its opioid and baby powder products. No surprise, the company has been impacted by COVID-19 in various ways; while its pharma division is racing to develop a vaccine, sales of products like artificial knees and hips are down due to the cancellation of elective surgeries during the pandemic.
Lists ranking Johnson & Johnson
Fortune 500 - 2020This year's Fortune 500 marks the 66th running of ...READ MORE
World’s Most Admired Companies - 2020For an astounding 13th straight year, Apple claims...READ MORE
Global 500 - 2019This year's Global 500 generated $27.7 trillion in...READ MORE
Change the World - 2018Here’s our look at 57 companies that do well by do...READ MORE
Created with sketchtool.Created with sketchtool.Leads, insights, and financial data for the FORTUNE 500, FORTUNE 1000, and Global 500 companies.Purchase Now